INSMED INC (INSM) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 1.14B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 188.22M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $1.14B | $188.22M | (m) |
| 2026-03-31 | (m) | $819.56M | $149.08M | (m) |
| 2025-12-31 | (m) | $606.42M | $122.94M | (m) |
| 2025-09-30 | (m) | $447.02M | $104.87M | (m) |
| 2025-06-30 | (m) | $398.11M | $96.67M | (m) |
| 2025-03-31 | (m) | $381.03M | $89.56M | (m) |
| 2024-12-31 | (m) | $363.71M | $85.74M | (m) |
| 2024-09-30 | (m) | $342.96M | $78.03M | (m) |
| 2024-06-30 | (m) | $328.61M | $73.57M | (m) |
| 2024-03-31 | (m) | $315.49M | $69.20M | (m) |
| 2023-12-31 | (m) | $305.21M | $65.57M | (m) |
| 2023-09-30 | (m) | $280.81M | $60.20M | (m) |
| 2023-06-30 | (m) | $269.47M | $56.96M | (m) |
| 2023-03-31 | (m) | $257.46M | $56.77M | (m) |
| 2022-12-31 | (m) | $245.36M | $55.13M | (m) |
| 2022-09-30 | (m) | $242.18M | $55.34M | (m) |
| 2022-06-30 | (m) | $221.21M | $52.06M | (m) |
| 2022-03-31 | (m) | $201.35M | $46.50M | (m) |
| 2021-12-31 | (m) | $188.46M | $44.15M | (m) |
| 2021-09-30 | (m) | $173.75M | $41.73M | (m) |
| 2021-06-30 | (m) | $170.64M | $42.16M | (m) |
| 2021-03-31 | (m) | $167.77M | $41.28M | (m) |
| 2020-12-31 | (m) | $164.41M | $39.87M | (m) |
| 2020-09-30 | $130.99M | $168.71M | $37.72M | 77.64% |
| 2020-06-30 | $130.42M | $163.95M | $33.53M | 79.55% |
| 2020-03-31 | $122.92M | $151.43M | $28.50M | 81.18% |
| 2019-12-31 | $112.25M | $136.47M | $24.21M | 82.26% |
| 2019-09-30 | (m) | $100.59M | $17.93M | (m) |
| 2019-06-30 | (m) | $61.71M | $11.49M | (m) |
| 2019-03-31 | (m) | $31.74M | $6.57M | (m) |
| 2018-12-31 | (m) | $9.84M | $2.42M | (m) |
| 2018-09-30 | (m) | $0.00 | (m) | (m) |
| 2018-06-30 | (m) | $0.00 | (m) | (m) |
| 2018-03-31 | (m) | $0.00 | (m) | (m) |
| 2017-12-31 | (m) | $0.00 | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $0.00 | (m) | (m) |
| 2017-03-31 | (m) | $0.00 | (m) | (m) |
| 2016-12-31 | (m) | $0.00 | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $0.00 | (m) | (m) |
| 2013-12-31 | (m) | $11.50M | (m) | (m) |
| 2013-09-30 | (m) | $11.50M | (m) | (m) |
| 2013-06-30 | (m) | $11.50M | (m) | (m) |
| 2012-12-31 | (m) | $0.00 | (m) | (m) |
| 2012-09-30 | (m) | $1.40M | (m) | (m) |
| 2012-06-30 | (m) | $1.84M | (m) | (m) |
| 2012-03-31 | (m) | $2.82M | (m) | (m) |
| 2011-12-31 | (m) | $4.42M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $6.92M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $10.37M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |